Fulgent Genetics (FLGT) Cash & Current Investments (2016 - 2026)
Fulgent Genetics' Cash & Current Investments history spans 12 years, with the latest figure at $276.3 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 13.74% to $276.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $276.3 million, a 13.74% decrease, with the full-year FY2025 number at $336.1 million, up 30.21% from a year prior.
- Cash & Current Investments hit $276.3 million in Q1 2026 for Fulgent Genetics, down from $336.1 million in the prior quarter.
- Over the last five years, Cash & Current Investments for FLGT hit a ceiling of $585.1 million in Q1 2022 and a floor of $213.1 million in Q3 2024.
- Historically, Cash & Current Investments has averaged $385.3 million across 5 years, with a median of $375.8 million in 2025.
- Biggest five-year swings in Cash & Current Investments: soared 87.02% in 2022 and later plummeted 54.45% in 2024.
- Tracing FLGT's Cash & Current Investments over 5 years: stood at $526.2 million in 2022, then fell by 19.4% to $424.2 million in 2023, then tumbled by 39.15% to $258.1 million in 2024, then soared by 30.21% to $336.1 million in 2025, then dropped by 17.79% to $276.3 million in 2026.
- Business Quant data shows Cash & Current Investments for FLGT at $276.3 million in Q1 2026, $336.1 million in Q4 2025, and $375.8 million in Q3 2025.